Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SEATTLE, Feb. 12, 2016 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release fourth quarter 2015 financial results after the close of trading on Monday, February 29, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and to provide a business update.
Individuals interested in listening to the conference call may do so by dialing (888) 793-9492 for domestic callers, or (734) 385-2643 for international callers. Please reference Conference ID: 38816043. To listen to a live webcast, please visit the investor relations section of the company’s website at: www.nanostring.com.
A replay of the call will be available beginning February 29, 2016 at 7:30pm ET through midnight on March 1, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 38816043. The webcast will also be available on the company’s website for one year following the completion of the call.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies [email protected] 415-513-1281
